Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Florida
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Children's National Research Institute
St. Jude Children's Research Hospital
ITM Solucin GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
University of Wisconsin, Madison
Novartis
Valent Technologies, LLC
Fudan University
Nationwide Children's Hospital
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Hospital of Philadelphia
City of Hope Medical Center
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
University of Virginia
Bayer
Memorial Sloan Kettering Cancer Center
University Hospital, Basel, Switzerland
Masonic Cancer Center, University of Minnesota
Bayer
Emory University